UPDATE 1-India's Dr. Reddy's Q3 profit tumbles, hit by U.S. pricing pressure [Reuters (UK)]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Reuters
India's Dr. Reddy's third-quarter profit tumbles, hit by U.S. pricing pressure | Reuters Reuters Staff 2 Min Read (Reuters) - Indian generic drugmaker Dr. Reddy’s Laboratories Ltd said quarterly net profit slumped nearly 40 percent, its third consecutive quarter of declines as pricing pressures in the United States hit sales. Indian drugmakers have faced challenges in negotiating prices as a result of consolidation among drug distributors in the United States, the world’s biggest pharmaceuticals market. Like many of its domestic rivals, Dr Reddy’s has also been hit by U.S. bans on Indian plants over quality control issues. Net profit fell 38.5 percent to 3.03 billion rupees ($47.7 million) in the third quarter ended Dec. 31, below an average analyst estimate of 3.4 billion rupees. Revenue from the company’s generics business in North America fell 3 percent to 16.07 billion rupees. Revenue from its Europe generics business dropped 7 percent to 2.01 billion rupees due to pricing pressur
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Indian shares set to open higher tracking Asian peers [Reuters]Reuters
- Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India [Yahoo! Finance]Yahoo! Finance
- Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in IndiaGlobeNewswire
- Global Freeze Drying Market Size To Exceed USD 10.9 Billion By 2033 | CAGR of 8.55% [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics GAAP EPS of -$0.79 [Seeking Alpha]Seeking Alpha
RDY
Earnings
- 1/31/24 - Beat
RDY
Sec Filings
- 3/27/24 - Form 6-K
- 3/22/24 - Form 6-K
- 3/22/24 - Form 6-K
- RDY's page on the SEC website